AB BioArctic unveiled collaboration, option & license agreement with Novartis Pharma AG for a potential new treatment combining BioArctic's proprietary BrainTransporter technology with an undisclosed target in neurodegeneration. In this initiative BioArctic will receive USD 30 million in upfront payment. https://www.coherentmarketinsights.com/news/ab-bioarctic-unveils-collaboration-option-license-agreement-with-novartis-pharma-ag-1401